It has been demonstrated that the intraperitoneal administration of 10 mg/kg MCC950, an NLR family pyridine structure domain 3 (NLRP3) inflammatory vesicle inhibitor, resulted in the inhibition of collagen type I alpha 1 chain (COL1A1), collagen type III alpha 1 chain (COL3A1) and α-Smooth muscle actin (α-SMA) expression in the myocardium of mice with MI. Here, COL1A1 is linked to myocardial infarction.